This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Mark Behlke, M.D., Ph.D.
Chief Scientific Officer at Integrated DNA Technologies, Inc.

Profile

As the Chief Scientific Officer, Dr. Behlke has directed research activities at IDT since joining the company in 1995 with a focus on novel molecular biology applications of oligonucleotide-based technologies.  In addition, Dr. Behlke is also a scientific co-founder of Dicerna Pharmaceuticals, located in Boston.  Before joining IDT, Dr. Behlke was a Physician Postdoctoral Fellow of the Howard Hughes Medical Institute at the Whitehead Institute, MIT.  He was a Resident Physician in Internal Medicine at Brigham and Women’s Hospital, Boston.  Dr. Behlke received his M.D. and Ph.D. degrees from Washington University, St. Louis in 1988 and his B.S. degree from the Massachusetts Institute of Technology in 1981.  Dr. Behlke is an inventor on over 45 issued US patents, has numerous pending patent applications, and is an author on over 130 scientific publications and book chapters.  He is a recognized expert on oligonucleotide-based technologies.